Sitagliptin and the Risk for Hypoglycaemia in Type 2 Diabetes Patients

NCT03359590 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Pharmacological Action

Interventions

DRUG: Sitagliptin 100 mg
DRUG: Placebo

Sponsor

Profil Institut für Stoffwechselforschung GmbH

Collaborators

[object Object]